Integrin alpha L beta 2

Integrin alpha L beta 2 Molekülinformation

Englischer Name	Integrin alpha-L/beta-2 (LFA-1)	Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	1	Target-Alias	Lymphocyte Function-Associated Antigen-1
Höchste Forschungs- und Entwicklungsphase	Approved

Englischer Name	Integrin alpha-L/beta-2 (LFA-1)
Target-Alias	Lymphocyte Function-Associated Antigen-1
Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	1
Höchste Forschungs- und Entwicklungsphase	Approved

Integrin alpha L beta 2 Produktliste

Attribut
Protein (1)
Produktbibliothek
Online (1)
Spezies
Human (1)
Etikett
His Tag (1)
Marker
Unconjugated (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
IT2-H53W3	Human	CHO	Human Integrin alpha L beta 2 (ITGAL&ITGB2) Heterodimer Protein, His Tag&Tag Free, low endotoxin (MALS verified)				In den Warenkorb legen

Gesamtmenge1

Integrin alpha L beta 2 Molekülhintergrund

Integrin alpha-L beta-2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4. Integrin alpha L beta 2 is also a receptor for F11R (By similarity). Involved in a variety of immune phenomena including leukocyte-endothelial cell interaction, cytotoxic T-cell mediated killing, and antibody dependent killing by granulocytes and monocytes. Contributes to natural killer cell cytotoxicity. Involved in leukocyte adhesion and transmigration of leukocytes including T-cells and neutrophils. Required for generation of common lymphoid progenitor cells in bone marrow, indicating the role in lymphopoiesis. Integrin alpha L beta 2 in association with ICAM3, contributes to apoptotic neutrophil phagocytosis by macrophages.

Integrin alpha L beta 2 Molekülalias

Integrin alpha L beta 2,ITGAL&ITGB2

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Alintegimod	7HP349; 7-HP-349; 7HP-349	Phase 2 Clinical	7 Hills Pharma LLC	Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Chagas Disease; Colorectal Neoplasms; Coronavirus Disease 2019 (COVID-19); Influenza, Human; Kidney Neoplasms; Lymphoma; Melanoma; Mesothelioma; Mismatch Repair Deficient Cancer; Neoplasm Metastasis; Neoplasms; Skin Neoplasms; Solid tumours; Tuberculosis	Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Lifitegrast	SHP-606; SAR-1119; SAR-1118; SPD-606; OJL-332	Approved	Shire Development Llc	Xiidra, 朗悦明	United States	Dry Eye Syndromes	Bausch And Lomb Inc	2016-07-11	Conjunctivitis, Allergic; Diabetic macular oedema; Dry Eye Syndromes; Graft vs Host Disease; Keratoconjunctivitis Sicca; Xerophthalmia	Details